UPDATE -- Breathtec Biomedical Provides Development Update on Breathalyzer for Disease Detection
January 25 2018 - 9:27AM
Please note this is an Official Company News
Release.
Breathtec Biomedical Inc. (CSE:BTH) (CNSX:BTH)
(FRANKFURT:BTI) (OTCQB:BTHCF) (the “Company”) is pleased to
report on the development of its Breathtec Disease Detection
Breathalyzer (“V2”) prototype based on the FAIMS (field
asymmetric waveform ion mobility spectrometry) technology. In
collaboration with Cannabix Technologies (CSE:BLO), the V2
prototype is now complete. The new device, classified as “V3” is
designed to operate both independently with its own self-contained
FAIMS detector, or coupled in tandem directly to a
triple-quadrupole Mass Spectrometer (MS) device. The device also
incorporates several technological enhancements, including a
modular design for faster iterative development, as well as size
reduction into a compact Point-of-Care (POC) design.
Preliminary bench testing indicates a direct correlation between
the V3 device and the MS. The MS is considered the gold standard in
biomarker detection and it is anticipated that any results from a
breathalyzer for disease detection will have to be independently
verified by MS.
The Company plans to further develop the V3 device and implement
findings from ongoing research conducted on biomarkers found in the
breath that are associated with diseases, and continue on the path
of developing hand-held Breathtec Disease Detection Breathalyzers
to be non-invasive and highly accurate detection methods for
various diseases.
CTO Mike Costanzo states, “Breathtec Biomedical remains
dedicated to the development of a highly sensitive breathalyzer for
disease detection. With our collaboration with Cannabix and the
Vancouver Technical Team, we can expedite the testing and analysis
of biomarkers related to disease.”
Update on Management
Breathtec Biomedical is currently in advanced talks with
candidates for CEO to lead Breathtec Biomedical and will make
announcements as the company progresses in its evaluation of
candidates.
ON BEHALF OF THE BOARD “Michael Sadhra” Chief
Financial Officer & Director
ABOUT BREATHTEC BIOMEDICAL INC. Breathtec
Biomedical, Inc. (“Breathtec”) was formed to propel innovative
research in the area of airborne analysis as a medical screening
tool. Our efforts are aimed at leading the development of
commercially viable methods for the early screening of certain
pathogens. Our primary avenue of investigation is focused on
innovation and advances in the field of specialized mass
spectrometry. For more information,
visit www.breathtecbiomedical.com.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has
reviewed nor accepts responsibility for the adequacy or accuracy of
the content of this news release. This news release contains
forward-looking statements relating to product development,
licensing, commercialization and regulatory compliance issues and
other statements that are not historical facts. Forward-looking
statements are often identified by terms such as “will”, “may”,
“should”, “anticipate”, “expects” and similar expressions. All
statements other than statements of historical fact, included in
this release are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements.
Important factors that could cause actual results to differ
materially from the Company’s expectations include the failure to
satisfy the conditions of the relevant securities exchange(s) and
other risks detailed from time to time in the filings made by the
Company with securities regulations. The reader is cautioned that
assumptions used in the preparation of any forward-looking
information may prove to be incorrect. Events or circumstances may
cause actual results to differ materially from those predicted, as
a result of numerous known and unknown risks, uncertainties, and
other factors, many of which are beyond the control of the Company.
The reader is cautioned not to place undue reliance on any
forward-looking information. Such information, although considered
reasonable by management at the time of preparation, may prove to
be incorrect and actual results may differ materially from those
anticipated. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements as
expressly required by applicable law.
CONTACT:Alfred WongTel: 604 398
8840 ext
700info@breathtechbiomedical.cominvestors@breathtecbiomedical.comwww.breathtecbiomedical.com